FORA Capital LLC Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

FORA Capital LLC bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 25,933 shares of the biopharmaceutical company's stock, valued at approximately $516,000.

A number of other institutional investors also recently bought and sold shares of the company. Susquehanna Fundamental Investments LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 2nd quarter valued at $258,000. Integral Health Asset Management LLC bought a new stake in Catalyst Pharmaceuticals during the second quarter valued at about $4,260,000. GSA Capital Partners LLP bought a new stake in Catalyst Pharmaceuticals during the third quarter valued at about $625,000. Vanguard Group Inc. increased its position in Catalyst Pharmaceuticals by 12.1% in the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company's stock worth $127,212,000 after buying an additional 860,244 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Catalyst Pharmaceuticals by 146.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company's stock valued at $7,285,000 after buying an additional 217,956 shares in the last quarter. Institutional investors own 79.22% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Truist Financial increased their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a report on Monday, November 11th. Citigroup upped their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a "buy" rating in a report on Friday, August 9th. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, August 9th. Finally, Stephens assumed coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They issued an "overweight" rating and a $35.00 price target for the company. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $31.14.

Catalyst Pharmaceuticals Trading Down 1.2 %

Shares of CPRX stock traded down $0.27 on Friday, reaching $22.07. The company's stock had a trading volume of 554,323 shares, compared to its average volume of 1,187,151. The stock's fifty day simple moving average is $21.23 and its 200-day simple moving average is $18.72. Catalyst Pharmaceuticals, Inc. has a 1 year low of $13.00 and a 1 year high of $24.27. The company has a market capitalization of $2.63 billion, a price-to-earnings ratio of 18.70, a price-to-earnings-growth ratio of 3.44 and a beta of 0.75.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.